UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)

BMC cancer, 2024-01, Vol.24 (1), p.91-91, Article 91

2024

Volltextzugriff (PDF)

HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis

Journal of Gynecologic Oncology, 2022, 33(3), , pp.1-18

2022

Volltextzugriff (PDF)

Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211042691-17588359211042691

2021

Volltextzugriff (PDF)

Efficacy of HPV vaccination among seropositive, DNA negative cohorts

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.10552-10552

2021

Volltextzugriff (PDF)

Modifiable risk factors and risk of colorectal and endometrial cancer in Lynch syndrome: A systematic review and meta-analysis

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e22544-e22544

2023

Volltextzugriff (PDF)

Single-arm phase 2 clinical trial evaluating neoadjuvant abiraterone and gonadotrophin-releasing hormone agonist in high-risk localised prostate carcinoma: CTRIAL-IE (ICORG) 13-23

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.360-360

2023

Volltextzugriff (PDF)

HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis

Journal of gynecologic oncology, 2022-05, Vol.33 (3), p.1

2022

Volltextzugriff (PDF)

Neoadjuvant trastuzumab deruxtecan

BMC cancer, 2024-01, Vol.24 (1)

2024

Volltextzugriff (PDF)

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Blood, 2021-11, Vol.138 (Supplement 1), p.2756-2756

2021

Volltextzugriff (PDF)

Efficacy and toxicity of primary re-irradiation for malignant spinal cord compression based on radiobiological modelling: a phase II clinical trial

British journal of cancer, 2023-02, Vol.128 (4), p.576-585

2023

Volltextzugriff (PDF)

Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis

JOURNAL OF CLINICAL ONCOLOGY, 2023, Vol.41 (4_suppl), p.295-295

2023

Volltextzugriff (PDF)

Abstract P5-16-08: Phase Ib/II trial evaluating safety and efficacy of copanlisib (PI3K inhibitor) and trastuzumab in pre-treated advanced HER2-positive breast cancer: Results from the PantHER study

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-16-08

2022

Volltextzugriff (PDF)

Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study

Journal of Gynecologic Oncology, 2022, 33(3), , pp.1-14

2022

Volltextzugriff (PDF)

Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compression

British journal of cancer, 2020-04, Vol.122 (9), p.1315-1323

2020

Volltextzugriff (PDF)

Phase II safety and tolerability study of Radium-223 (R223) in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CTRIAL-IE (ICORG) 13-21

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5050-5050

2018

Volltextzugriff (PDF)

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

The lancet. Gastroenterology & hepatology, 2023-11, Vol.8 (11), p.1015-1027

2023

Volltextzugriff (PDF)

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Blood, 2017-12, Vol.130, p.3163-3163

2017

Volltextzugriff (PDF)

An updated analysis evaluating skeletal related events (SREs) in CTRIAL-IE 13-21: Phase II trial of radium-223 (R223) in combination with enzalutamide (ENZA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.215-215

2019

Volltextzugriff (PDF)

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Blood, 2018-11, Vol.132 (Supplement 1), p.3242-3242

2018

Volltextzugriff (PDF)

Abstract P1-19-24: A phase Ib trial of copanlisib in combination with trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-19-24

2020

Volltextzugriff (PDF)

Modifiable Risk Factors and Risk of Colorectal and Endometrial Cancers in Lynch Syndrome: A Systematic Review and Meta-Analysis

JCO precision oncology, 2024-01, Vol.8 (8), p.e2300196

2024

Volltextzugriff (PDF)

A phase Ib trial of copanlisib and tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1036-1036

2018

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(45)

Publikationsform

Sprache

Englisch
(48)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(11)
Blood
(6)
Cancer Research
(4)
Journal Of Gynecologic Oncology
(3)
Bmc Cancer
(2)
British Journal Of Cancer
(2)
The Lancet
(2)
Therapeutic Advances In Medical Oncology
(2)
Arthritis Care & Research
(1)
Bmj Open
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)

HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis

Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER"

Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study

Efficacy of HPV vaccination among seropositive, DNA negative cohorts

Modifiable risk factors and risk of colorectal and endometrial cancer in Lynch syndrome: A systematic review and meta-analysis

Single-arm phase 2 clinical trial evaluating neoadjuvant abiraterone and gonadotrophin-releasing hormone agonist in high-risk localised prostate carcinoma: CTRIAL-IE (ICORG) 13-23

HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis

Neoadjuvant trastuzumab deruxtecan

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Efficacy and toxicity of primary re-irradiation for malignant spinal cord compression based on radiobiological modelling: a phase II clinical trial

Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis

Abstract P5-16-08: Phase Ib/II trial evaluating safety and efficacy of copanlisib (PI3K inhibitor) and trastuzumab in pre-treated advanced HER2-positive breast cancer: Results from the PantHER study

Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study

Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compression

Phase II safety and tolerability study of Radium-223 (R223) in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CTRIAL-IE (ICORG) 13-21

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452)

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

An updated analysis evaluating skeletal related events (SREs) in CTRIAL-IE 13-21: Phase II trial of radium-223 (R223) in combination with enzalutamide (ENZA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Abstract P1-19-24: A phase Ib trial of copanlisib in combination with trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”

Abstract CT212: A phase III randomized study of paclitaxel (T) and trastuzumab (H) versus T, H and lapatinib (L) in first line treatment of HER2+ metastatic breast cancer (MBC)

Modifiable Risk Factors and Risk of Colorectal and Endometrial Cancers in Lynch Syndrome: A Systematic Review and Meta-Analysis

A phase Ib trial of copanlisib and tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”

Suchergebnisse filtern